533 related articles for article (PubMed ID: 27882532)
1. Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.
Berger T; Elovaara I; Fredrikson S; McGuigan C; Moiola L; Myhr KM; Oreja-Guevara C; Stoliarov I; Zettl UK
CNS Drugs; 2017 Jan; 31(1):33-50. PubMed ID: 27882532
[TBL] [Abstract][Full Text] [Related]
2. Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.
Lambert C; Dubois B; Dive D; Lysandropoulos A; Selleslag D; Vanopdenbosch L; Van Pesch V; Vanwijmeersch B; Janssens A
Acta Neurol Belg; 2018 Mar; 118(1):7-11. PubMed ID: 29380254
[TBL] [Abstract][Full Text] [Related]
3. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
[TBL] [Abstract][Full Text] [Related]
4. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
Devonshire V; Phillips R; Wass H; Da Roza G; Senior P
J Neurol; 2018 Nov; 265(11):2494-2505. PubMed ID: 29525836
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis.
Garnock-Jones KP
Drugs; 2014 Mar; 74(4):489-504. PubMed ID: 24604792
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis.
Zmira O; Halpern AI; Abraham L; Achiron A
Acta Neurol Belg; 2021 Dec; 121(6):1513-1518. PubMed ID: 32447722
[TBL] [Abstract][Full Text] [Related]
7. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
Oh J; Achiron A; Celius EG; Chambers C; Derwenskus J; Devonshire V; Hellwig K; Hutton GJ; McCombe P; Moore M; Rog D; Schneider JR; Simm RF; Sousa L; Vincent SG; Chung L; Daizadeh N; Mitchell C; Compston DAS;
Mult Scler Relat Disord; 2020 Aug; 43():102146. PubMed ID: 32498033
[TBL] [Abstract][Full Text] [Related]
8. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab (LEMTRADA) and multiple sclerosis. Biased evaluation, evidence of serious risks.
Prescrire Int; 2015 Mar; 24(158):69. PubMed ID: 25897458
[TBL] [Abstract][Full Text] [Related]
10. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab treatment of multiple sclerosis.
Coles AJ
Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214
[TBL] [Abstract][Full Text] [Related]
13. Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
Ranganathan U; Kaunzner U; Foster S; Vartanian T; Perumal JS
Mult Scler; 2018 Apr; 24(4):540-542. PubMed ID: 28287030
[TBL] [Abstract][Full Text] [Related]
14. Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus.
Sprangers B; Decoo D; Dive D; Lysandropoulos A; Vanopdenbosch L; Bovy C
Acta Neurol Belg; 2018 Jun; 118(2):143-151. PubMed ID: 29189966
[TBL] [Abstract][Full Text] [Related]
15. [Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)].
Khachanova NV; Bakhtiyarova KZ; Boyko AN; Vlasov YV; Davydovskaya MV; Evdoshenko EP; Zakharova MN; Kotov SV; Popova EV; Sivertseva SA; Totolyan NA; Khabirov FA
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(3):82-91. PubMed ID: 32323949
[TBL] [Abstract][Full Text] [Related]
16. Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.
Deleu D; Mesraoua B; El Khider H; Canibano B; Melikyan G; Al Hail H; Mhjob N; Bhagat A; Ibrahim F; Hanssens Y
Curr Med Res Opin; 2017 Mar; 33(3):439-458. PubMed ID: 27892723
[TBL] [Abstract][Full Text] [Related]
17. Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).
Ziemssen T; Engelmann U; Jahn S; Leptich A; Kern R; Hassoun L; Thomas K
BMC Neurol; 2016 Jul; 16():109. PubMed ID: 27430352
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
19. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.
Barclay K; Carruthers R; Traboulsee A; Bass AD; LaGanke C; Bertolotto A; Boster A; Celius EG; de Seze J; Cruz DD; Habek M; Lee JM; Limmroth V; Meuth SG; Oreja-Guevara C; Pagnotta P; Vos C; Ziemssen T; Baker DP; Wijmeersch BV
Front Neurol; 2019; 10():253. PubMed ID: 30967831
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab for Multiple Sclerosis.
Willis MD; Robertson NP
Curr Neurol Neurosci Rep; 2016 Sep; 16(9):84. PubMed ID: 27485945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
